Evidence map›Paper›PMID 40976850›Full record

ArticleBritish journal of haematology2025

The epidemiological landscape of bloodstream infections in children undergoing chemotherapy or haematopoietic cell transplantation: A retrospective study by Infectious Diseases Working Group of Italian Association of Pediatric Hematology and Oncology (AIEOP).

Francesco Baccelli, Francesca Compagno, Gloria Tridello, Francesco Delle Cave, Daniele Zama, Riccardo Masetti, Maria Grazia Petris, Lorenzo Chiusaroli, Manuela Spadea, Francesca Trevisan and 18 more

Abstract readMulticenter Study
In one paragraph

Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Clinical Analysis ofPathogens (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Francesco BaccelliPediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.ORCID https://orcid.org/0000-0001-8313-7288
Francesca CompagnoPaediatric Haematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Gloria TridelloPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Francesco Delle CavePaediatric Haematology and Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Daniele ZamaPediatric Emergency Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Riccardo MasettiPediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Maria Grazia PetrisClinic of Pediatric Hemato-Oncology, Department of Women's and Children's Health, Clinic of Pediatric Hemato-Oncology, University of Padua, Padua, Italy.
Lorenzo ChiusaroliDivision of Pediatric Infectious Diseases, Department for Women's and Children's Health, University Hospital of Padua, Padua, Italy.
Manuela SpadeaPediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.ORCID https://orcid.org/0000-0001-7728-904X
Francesca TrevisanMeyer Pediatric Onco-Hematology Unit-AOU Meyer Firenze, Florence, Italy.
Antonella ColombiniFondazione IRCCS, Ospedale San Gerardo dei Tintori, Monza, Italy.
Samantha ConciPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Cristina MeazzaPediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paola MuggeoPediatric Oncology-Hematology Unit, Department of Pediatrics, Azienda Ospedaliero Universitaria Policlinico, Bari, Italy.
Maria Vittoria MichelettiPediatric Hematology, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Alessia PancaldiPediatric Oncology and Hematology Unit, Department of Medical and Surgical Sciences for Mother Children and Adults, University of Modena and Reggio Emilia, Modena, Italy.
Rosamaria MuraPediatric Onco-Hematology Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Daniela OnofrilloHematology Unit, Hospital of Pescara, Pescara, Italy.
Raffaella De SantisPediatric Hematology Oncology, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy.
Milena La SpinaPediatric Hematology and Oncology Unit, AOU Policlinico "Rodolico-San Marco", University of Catania, Catania, Italy.
Elio CastagnolaInfectious Diseases Unit, Istituto Giannina Gaslini Children's Hospital, Genoa, Italy.
Katia PerruccioPediatric Oncology Hematology, Mother and Child Health Department, Santa Maria della Misericordia Hospital, Perugia, Italy.
Angelica BaronePediatric Onco-Hematology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Nagua GiuriciPediatric Hematology-Oncology, Institute for Maternal and Child Health IRCCS "Burlo Garofolo", Trieste, Italy.
Angelamaria PetroneU.O.M. Pediatria, Ospedale S. Chiara, Trento, Italy.
Federico MercoliniPediatric Onco-Hematology Unit, Department of Pediatrics, Hospital of Bolzano, Bolzano, Italy.
Simona RinieriPediatric Unit, Onco-Hematology Day Hospital, Sant'Anna Hospital, Ferrara, Italy.
Simone CesaroPediatric Hematology Oncology, Department of Mother and Child, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Funding

Italian Ministry of Health RC-2025-2791682
6 · The paper itself

Abstract

Understanding bloodstream infection (BSI) epidemiology is crucial for optimizing antibiotic therapy in paediatric haematology-oncology patients undergoing chemotherapy or haematopoietic cell transplantation (HCT). However, updated paediatric data remain scarce. This multicentre retrospective study analysed BSI epidemiology across 22 Italian centres (2018-2019), assessing pathogens, resistance profiles, empirical antibiotic therapy (EAT) and clinical course with outcomes. Mortality risk factors were evaluated using a Cox regression model. A total of 510 BSI episodes occurred in 396 patients (median age 6.4 years), with an incidence of 2.9 and 5.1 per 1000 inpatient days for chemotherapy and HCT respectively. Multidrug-resistant (MDR), third to fourth generation cephalosporin- and carbapenem-resistant, account for 18.3%, 29.3% and 8.2% of Gram-negative infections respectively. 42.2% of Klebsiella pneumoniae isolates were MDR. Combination EAT was used in 269/510 episodes, with piperacillin-tazobactam+amikacin being most common. Microbiological appropriateness was 82%. Infection-related and 30-day mortality rates were 4.1% and 5.29%, respectively, with appropriate EAT significantly reducing mortality. Our findings highlight the burden of resistant pathogens in paediatric BSIs and emphasize the importance of appropriate EAT in improving outcomes, underscoring the need for treatment strategies tailored to local resistance patterns.

Indexed as

BacteremiaHematopoietic Stem Cell TransplantationSepsisAdolescentAnti-Bacterial AgentsChildChild, PreschoolFemaleHumansInfantItalyMaleRetrospective StudiesRisk FactorsAnti-Bacterial Agentsantimicrobial resistancebloodstream infectionsempirical antibiotic therapyfebrile neutropeniahaematopoietic cell transplantationpaediatric haematologypaediatric oncology

Identifiers

PMID40976850
PMCPMC12624170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.